Skip to main content
Top
Published in: Infection 3/2013

01-06-2013 | Clinical and Epidemiological Study

Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination

Authors: A.-L. Munier, V. de Lastours, E. Varon, J.-L. Donay, R. Porcher, J.-M. Molina

Published in: Infection | Issue 3/2013

Login to get access

Abstract

Purpose

Invasive pneumococcal diseases (IPD) remain frequent and severe events in human immunodeficiency virus (HIV)-infected subjects despite the use of antiretroviral therapy and the availability of vaccines. Our aim was to assess the antibiotic susceptibilities and serotypes of strains responsible for IPD in HIV-infected patients.

Methods

We retrospectively analyzed all Streptococcus pneumoniae strains isolated from normally sterile sites between 2000 and 2011 in HIV-infected patients from a single reference center in Paris. The minimum inhibitory concentrations were determined by the E-test, and serotyping was performed by the antiserum agglutination method.

Results

Among our study group, 41 HIV-infected adults presented 43 IPD during the study period. Of these 41 patients, 78 % were men, and the median age was 43 (range 23–62) years. the median CD4 cell count was 184/mm3 (6–1,090/mm3), 51 % were receiving antiretroviral therapy, and 24 % had plasma HIV-RNA levels of <400 copies/mL. Only two patients had received the pneumococcal polysaccharide 23-valent vaccine (PPV23). Isolates were susceptible to penicillin G, amoxicillin, and cotrimoxazole in 44, 70, and 59 % of cases, respectively, and were significantly less susceptible to these antibiotics than isolates in the French general population during the same period. Among the 27 strains serotyped, 18 different serotypes were observed, of which 19A, 14, 7F, and 6A were the most frequent. Serotype distribution was similar to that in the French general population. The PPV23 vaccine and the 13-valent conjugate vaccine (PCV13) would have theoretically covered 78 and 70 % of cases, respectively.

Conclusions

In our HIV-infected patient cohort, S. pneumoniae isolates demonstrated higher levels of resistance to beta-lactamines and cotrimoxazole than in the French general population. HIV-infected patients should benefit from the herd protection effect expected from the large-scale vaccination of children by PCV13.
Literature
1.
go back to reference Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. AIDS. 2012;26:87–94.PubMedCrossRef Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. AIDS. 2012;26:87–94.PubMedCrossRef
2.
go back to reference Jordano Q, Falcó V, Almirante B, Planes AM, Del Valle O, Ribera E, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38:1623–8.PubMedCrossRef Jordano Q, Falcó V, Almirante B, Planes AM, Del Valle O, Ribera E, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38:1623–8.PubMedCrossRef
3.
go back to reference Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–54.PubMedCrossRef Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–54.PubMedCrossRef
4.
go back to reference McEllistrem MC, Mendelsohn AB, Pass MA, Elliott JA, Whitney CG, Kolano JA, et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis. 2002;185:1364–8.PubMedCrossRef McEllistrem MC, Mendelsohn AB, Pass MA, Elliott JA, Whitney CG, Kolano JA, et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis. 2002;185:1364–8.PubMedCrossRef
5.
go back to reference Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86.PubMedCrossRef Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86.PubMedCrossRef
6.
go back to reference Grau I, Ardanuy C, Liñares J, Podzamczer D, Schulze MH, Pallares R. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med. 2009;10:488–95.PubMedCrossRef Grau I, Ardanuy C, Liñares J, Podzamczer D, Schulze MH, Pallares R. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med. 2009;10:488–95.PubMedCrossRef
7.
go back to reference Paul J, Kimari J, Gilks CF. Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity. Lancet. 1995;346:1034–5.PubMedCrossRef Paul J, Kimari J, Gilks CF. Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity. Lancet. 1995;346:1034–5.PubMedCrossRef
8.
go back to reference Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS. 2006;20:437–44.PubMedCrossRef Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS. 2006;20:437–44.PubMedCrossRef
9.
go back to reference Peñaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A, et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis. 2007;45:e82–7.PubMedCrossRef Peñaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A, et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis. 2007;45:e82–7.PubMedCrossRef
10.
go back to reference Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794–800.PubMedCrossRef Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794–800.PubMedCrossRef
11.
go back to reference Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005;165:1533–40.PubMedCrossRef Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005;165:1533–40.PubMedCrossRef
12.
go back to reference French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106–11.PubMedCrossRef French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106–11.PubMedCrossRef
13.
go back to reference Veras MASM, Enanoria WTA, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study. BMC Infect Dis. 2007;7:119.PubMedCrossRef Veras MASM, Enanoria WTA, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study. BMC Infect Dis. 2007;7:119.PubMedCrossRef
14.
go back to reference Pedersen R, Lohse N, Østergaard L, Søgaard O. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011;12:323–33.PubMedCrossRef Pedersen R, Lohse N, Østergaard L, Søgaard O. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011;12:323–33.PubMedCrossRef
15.
go back to reference Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J. 2009;180:48–58.CrossRef Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J. 2009;180:48–58.CrossRef
16.
go back to reference Mohseni-Zadeh M, Rey D, Batard M-L, Beck Wirth G, Partisani M-L, Lang J-M, et al. Inadequate vaccination coverage in a French cohort of HIV positive patients. Med Mal Infect. 2010;40:683–90.PubMedCrossRef Mohseni-Zadeh M, Rey D, Batard M-L, Beck Wirth G, Partisani M-L, Lang J-M, et al. Inadequate vaccination coverage in a French cohort of HIV positive patients. Med Mal Infect. 2010;40:683–90.PubMedCrossRef
17.
go back to reference Centers for Disease Control. General recommendations on immunization. Guidelines from the immunization practices advisory committee. Ann Intern Med. 1989;111:133–42.CrossRef Centers for Disease Control. General recommendations on immunization. Guidelines from the immunization practices advisory committee. Ann Intern Med. 1989;111:133–42.CrossRef
18.
go back to reference Guillemot D, Varon E, Bernède C, Weber P, Henriet L, Simon S, et al. Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. Clin Infect Dis. 2005;41:930–8.PubMedCrossRef Guillemot D, Varon E, Bernède C, Weber P, Henriet L, Simon S, et al. Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. Clin Infect Dis. 2005;41:930–8.PubMedCrossRef
20.
go back to reference Meynard JL, Barbut F, Blum L, Guiguet M, Chouaid C, Meyohas MC, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;22:437–40.PubMedCrossRef Meynard JL, Barbut F, Blum L, Guiguet M, Chouaid C, Meyohas MC, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;22:437–40.PubMedCrossRef
21.
go back to reference Kempf M, Baraduc R, Bonnabau H, Brun M, Chabanon G, Chardon H, et al. Epidemiology and antimicrobial resistance of Streptococcus pneumoniae in France in 2007: data from the pneumococcus surveillance network. Microb Drug Resist. 2011;17:31–6.PubMedCrossRef Kempf M, Baraduc R, Bonnabau H, Brun M, Chabanon G, Chardon H, et al. Epidemiology and antimicrobial resistance of Streptococcus pneumoniae in France in 2007: data from the pneumococcus surveillance network. Microb Drug Resist. 2011;17:31–6.PubMedCrossRef
22.
go back to reference Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis. 2008;47:1388–95.PubMedCrossRef Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis. 2008;47:1388–95.PubMedCrossRef
23.
go back to reference Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med. 2006;144:1–9.PubMedCrossRef Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med. 2006;144:1–9.PubMedCrossRef
24.
go back to reference Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83–93.PubMed Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83–93.PubMed
25.
go back to reference Musher DM. Pneumococcal vaccine-direct and indirect (“herd”) effects. N Engl J Med. 2006;354:1522–4.PubMedCrossRef Musher DM. Pneumococcal vaccine-direct and indirect (“herd”) effects. N Engl J Med. 2006;354:1522–4.PubMedCrossRef
26.
go back to reference Janoff EN, Fasching C, Ojoo JC, O’Brien J, Gilks CF. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis. 1997;175:975–8.PubMedCrossRef Janoff EN, Fasching C, Ojoo JC, O’Brien J, Gilks CF. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis. 1997;175:975–8.PubMedCrossRef
27.
go back to reference French N, Moore M, Haikala R, Kayhty H, Gilks CF. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis. 2004;190:707–12.PubMedCrossRef French N, Moore M, Haikala R, Kayhty H, Gilks CF. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis. 2004;190:707–12.PubMedCrossRef
28.
go back to reference French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362:812–22.PubMedCrossRef French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362:812–22.PubMedCrossRef
29.
go back to reference Lesprit P, Pédrono G, Molina J-M, Goujard C, Girard P-M, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007;21:2425–34.PubMedCrossRef Lesprit P, Pédrono G, Molina J-M, Goujard C, Girard P-M, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007;21:2425–34.PubMedCrossRef
30.
go back to reference Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–8.PubMedCrossRef Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–8.PubMedCrossRef
31.
go back to reference Crum-Cianflone NF, Roediger M, Huppler Hullsiek K, Ganesan A, Landrum M, Weintrob A, et al. The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine. 2010;28:7583–8.PubMedCrossRef Crum-Cianflone NF, Roediger M, Huppler Hullsiek K, Ganesan A, Landrum M, Weintrob A, et al. The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine. 2010;28:7583–8.PubMedCrossRef
32.
go back to reference Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816–819. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816–819.
Metadata
Title
Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination
Authors
A.-L. Munier
V. de Lastours
E. Varon
J.-L. Donay
R. Porcher
J.-M. Molina
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Infection / Issue 3/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0419-x

Other articles of this Issue 3/2013

Infection 3/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.